On May 28, Tempus AI rose 5.02% in regular trading, trading at $49.51/share, with trading volume of $60.40 million.

On the news front, the company recently announced a major upgrade to its Hub intelligent physician platform, deploying a next-generation Agentic AI architecture that integrates large language model and generative AI capabilities directly into the platform. The system combines real-time patient genomic data to provide proactive decision support for oncologists in precision medicine workflows.

Additionally, the company recently launched an AI-driven prostate cancer risk assessment test, the ArteraAI prostate test, which uses AI to analyze clinical data and biopsy images to estimate prostate cancer-specific mortality risk for metastatic hormone-sensitive prostate cancer patients.

On the financial side, Tempus AI reported Q1 revenue of $348.1 million, up 36.1% year-over-year and exceeding market expectations, with core diagnostics revenue growing 34.7% YoY, providing fundamental support for its technology expansion initiatives.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)